[Novel strategy and latest research progress on treatment of acute graft versus host disease].
Acute graft-versus-host disease (aGVHD) is the major complication associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the major cause of morbidity and mortality following allo-HSCT. Diagnosis of aGVHD is typically based on clinical symptoms and confirmed by biopsy. Once aGVHD has occurrence, the steroids should be the first choice of treatment. However, if the treatment with steroids failed, the prognosis would be poor. In recent years, the novel strategies for the treatment of aGVHD have been developed. In this article, the clinical features, pathogenesis and novel strategies, including mAb treatment, physical and cell therapies are briefly summarized.
Base for Training Postgradnates, Shengyang Military Command Gerenal Hospital, Liaoning Medical College, Shengyang 110016, Liaoning Province, China; Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Bo
B
Tang
Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Heng
H
Zhu
Base for Training Postgradnates, Shengyang Military Command Gerenal Hospital, Liaoning Medical College, Shengyang 110016, Liaoning Province, China. E-mail: zhoufan611@sina.com.cn.
Fan
F
Zhou
Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China. E-mail: zhangyi612@hotmail.com.
Yi
Y
Zhang
D000208:Acute Disease; D006086:Graft vs Host Disease / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D014184:Transplantation, Homologous / Q000009:adverse effects